Health Solutions
Prescription drugs
We review some commonly used drug-pricing terms in the U.S. pharmaceutical market, including their calculations and roles in the healthcare industry.
Drug costs are still rising, but trends begin to slow in Q3 2025
Practical considerations for financial forecasting
We discuss five key considerations for manufacturers negotiating Medicare Part D formulary access in the wake of the Inflation Reduction Act.
We discuss the implementation of the Medicare Prescription Payment Plan in 2025 and note some implications for 2026.
What state Medicaid programs should know and do ahead of the January 2026 launch
Utilization trends for non-low income Part D members show no signs of slowing in the first half of 2025
We detail factors in Phase-3 clinical trial design that influence health insurance coverage decisions.
A current perspective for patients with diabetes, hypertension, and hyperlipidemia
Medicare Advantage (MA) and Part D insurers are citing significant financial headwinds in earnings calls and the press. Statutory financial statements provide insights into emerging trends through year-end 2024.
